Meros Investment Management LP Has $814,000 Position in Harvard Bioscience, Inc. $HBIO

Meros Investment Management LP grew its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 32.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,217,628 shares of the medical instruments supplier’s stock after buying an additional 299,369 shares during the period. Meros Investment Management LP owned 2.72% of Harvard Bioscience worth $814,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Essex Investment Management Co. LLC acquired a new stake in shares of Harvard Bioscience in the fourth quarter valued at about $124,000. Renaissance Technologies LLC increased its stake in shares of Harvard Bioscience by 17.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,021,241 shares of the medical instruments supplier’s stock valued at $683,000 after buying an additional 152,763 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Harvard Bioscience by 291.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 37,057 shares during the period. Geode Capital Management LLC increased its stake in shares of Harvard Bioscience by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 460,793 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 18,923 shares during the period. Finally, Legato Capital Management LLC increased its stake in shares of Harvard Bioscience by 210.4% in the fourth quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 29,462 shares during the period. Institutional investors and hedge funds own 80.87% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HBIO. New Street Research set a $6.00 price target on Harvard Bioscience in a research note on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Friday, March 27th. Benchmark decreased their price target on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a research note on Friday, March 13th. Finally, Wall Street Zen cut Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.00.

Harvard Bioscience Trading Down 1.5%

NASDAQ HBIO opened at $5.99 on Tuesday. The business has a 50 day simple moving average of $5.98 and a 200 day simple moving average of $6.05. Harvard Bioscience, Inc. has a one year low of $3.75 and a one year high of $9.40. The stock has a market capitalization of $27.01 million, a P/E ratio of -2.76 and a beta of 1.53. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.99 and a quick ratio of 1.06.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Tuesday, May 12th. The medical instruments supplier reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.29. Harvard Bioscience had a negative return on equity of 25.78% and a negative net margin of 11.44%.The business had revenue of $20.76 million during the quarter, compared to analysts’ expectations of $21.20 million.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.